The “SWOT” of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The “SWOT” of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
Authors
Keywords
-
Journal
Current Oncology Reports
Volume 13, Issue 6, Pages 479-487
Publisher
Springer Nature
Online
2011-10-13
DOI
10.1007/s11912-011-0198-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- 4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
- (2010) Qing-Bai She et al. CANCER CELL
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
- (2010) Y. N. V. Gopal et al. CANCER RESEARCH
- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
- (2010) E. Halilovic et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
- (2010) C. A. Pratilas et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
- (2010) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- How melanomas bypass new therapy
- (2010) David Solit et al. NATURE
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
- (2010) Ruth Halaban et al. Pigment Cell & Melanoma Research
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
- (2010) S. Whittaker et al. Science Translational Medicine
- Pathologic Features and Biologic Importance of Colorectal Serrated Polyps
- (2009) Efsevia Vakiani et al. ADVANCES IN ANATOMIC PATHOLOGY
- Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
- (2009) R E Board et al. BRITISH JOURNAL OF CANCER
- Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
- (2009) Nathalie Dhomen et al. CANCER CELL
- BrafV600E cooperates with Pten loss to induce metastatic melanoma
- (2009) David Dankort et al. NATURE GENETICS
- An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors
- (2009) D Chitale et al. ONCOGENE
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer
- (2008) C. A. Pratilas et al. CANCER RESEARCH
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search